Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 6/20 | 0.58 |
| ▸ | QPCTL | Q9NXS2 | 5/20 | 0.58 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.51 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.51 |
| ▸ | IDO1 | P14902 | 5/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.49 |
| ▸ | PRKCI | P41743 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL991450 | 0.86 | CYP11B1 (0.51) | QPCTQPCTLCYP11B1CYP11B2IDO1 | |
| SCHEMBL8634290 | 0.81 | QPCT (0.68) | QPCTQPCTLSMN1; SMN2PRKCIMAPT | |
| SCHEMBL30718016 | 0.77 | CYP11B1 (0.53) | CYP11B1CYP11B2IDO1POLBSMN1; SMN2 | |
| SCHEMBL990029 | 0.77 | CYP11B1 (0.49) | CYP11B1CYP11B2IDO1POLBSMN1; SMN2 | |
| SCHEMBL2457533 | 0.76 | QPCT (0.54) | QPCTQPCTLSMN1; SMN2PRKCIMAPT | |
| SCHEMBL38665709 | 0.75 | QPCT (0.66) | QPCTQPCTLSMN1; SMN2PRKCIMAPT | |
| SCHEMBL7021141 | 0.75 | QPCT (0.66) | QPCTQPCTLSMN1; SMN2PRKCIMAPT | |
| SCHEMBL989969 | 0.74 | ASIC3 (0.51) | CYP11B1CYP11B2IDO1POLBSMN1; SMN2 | |
| SCHEMBL2474515 | 0.74 | QPCT (0.60) | QPCTQPCTLSMN1; SMN2PRKCIMAPT | |
| SCHEMBL26265591 | 0.74 | CYP11B1 (0.85) | CYP11B1CYP11B2IDO1POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7863310-B2 | Kinase inhibitors | ELI LILLY AND COMPANY (US) | 2011-01-04 | — | — | US | disclosed |
| US-20080227839-A1 | Kinase Inhibitors | ELI LILLY AND COMPANY | 2008-09-18 | — | — | US | disclosed |
| EP-1720862-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| WO-2005080380-A1 | KINASE INHIBITORS | ELI LILLY AND COMPANY (US) | 2005-09-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227839-A1 | Kinase Inhibitors | ABL1, MAP3K20, MAP3K19 | QPCT 3729/4885QPCTL 3953/4885CYP11B1 2916/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.